CNP-201

DRUG2 trials

Sponsors

COUR Pharmaceutical Development Company, Inc.

Conditions

Peanut Allergy

Phase 1

Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

TerminatedNCT04950504

COUR Pharmaceutical Development Company, Inc.Peanut Allergy

Start: 2021-06-02End: 2022-07-29Updated: 2023-09-18

CNP-201 in Subjects With Peanut Allergy

TerminatedNCT05250856

COUR Pharmaceutical Development Company, Inc.Peanut Allergy

Start: 2022-03-14End: 2023-12-12Updated: 2023-12-20